Insmed to Present at the 35th Annual J.P. Morgan Healthcare Conference
04 Janvier 2017 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today reported that the company will participate at the 35th Annual
J.P. Morgan Healthcare Conference on January 9-12, 2017 in San
Francisco. Will Lewis, president and chief executive officer of
Insmed, will deliver a corporate overview on Wednesday, January 11
at 7:30 AM PT.
Mr. Lewis’ presentation will be webcast live and can be accessed
by visiting the investor relations section of the company’s website
at www.insmed.com. The webcast will be archived for a period of 90
days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that is
capable of causing irreversible lung damage and can be fatal. There
are currently no products indicated for the treatment of NTM lung
disease in the United States or European
Union (EU). Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral inhibitor of dipeptidyl peptidase I with
therapeutic potential in non-cystic fibrosis bronchiectasis, and
INS1009, an inhaled prodrug formulation of treprostinil that may
offer a differentiated product profile for rare pulmonary
disorders. For more information, visit www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Investor Contact:
Laura Perry
Argot Partners
646.439.0410
laura@argotpartners.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024